immunogenicity and therapeutic targeting of recurrently mutated "public" neoantigens
Published 11 months ago • 767 plays • Length 53:45Download video MP4
Download video MP3
Similar videos
-
2:30
targeting public neoantigens in cancer immunotherapies
-
3:25
evaluating the therapeutic potential of pik3ca-derived public neoantigens
-
2:20
neoantigens: promising targets for cancer therapy
-
58:32
keynote - cancer immunology (carl h. june)
-
5:12
what are antigens and neoantigens?
-
49:06
"revisiting the neoantigen approach for cancer immunotherapy" by dr. yardena samuels
-
25:23
targeting tumor mutations for personalized cancer immunotherapy
-
2:20
neoantigens
-
1:45
optimizing public neoantigen-targeting immunotherapies
-
1:05:53
cancer immunotherapy beyond 2020
-
1:01
harnessing neoantigens for individualized cancer immunotherapy
-
1:01:22
cancer neoantigens as targets for natural and therapeutic anti-tumor responses
-
2:32
a brief background on neoantigen vaccines
-
56:13
cancer vaccines: are we closer?
-
4:04
neoantigens for melanoma treatment
-
1:04
research update: anticancer drug yields positive response - johns hopkins medicine
-
0:36
managing adrenocortical carcinoma with immunotherapies
-
23:51
efficient selection of tumor associated neoantigens in the design of personalized cancer vaccines
-
0:27
immuno-oncology